H.C. Wainwright Pounds The Table On Ocera Therapeutics Inc (OCRX)
H.C. Wainwright analyst Ed Arce was out pounding the table on Ocera Therapeutics Inc (NASDAQ:OCRX), reiterating a Buy rating and a $4.00 price target, which implies an upside of 180% from current levels.
Arce wrote, “With complete STOP-HE data in hand, Ocera is well positioned for a successful End-of-Phase-2 meeting with FDA in 3Q17 […] We believe that the complete data not only provided insight on why STOP-HE failed to reach its primary endpoint, but more importantly, established the main considerations for the Phase 3 design. Specifically, we will look for the Phase 3 trial to include: 1) a loading dose as well as an infusion dose of at least 20g to elicit a more pronounced treatment effect; 2) initiation of treatment promptly after randomization; 3) assessment of primary endpoint measurement at 48 hours post-infusion; and 4) exclusion of patients on rifaximin. We believe the incorporation of these changes into the Phase 3 design positions Ocera for a successful agreement with the FDA for a clear path forward which represents a major risk-reducing event.”
According to TipRanks, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Ed Arce has a yearly average return of 29.6% and a 47% success rate. Arce has a 31.2% average return when recommending OCRX, and is ranked #112 out of 4539 analysts.
Out of the 3 analysts polled in the past 12 months, 2 rate Ocera Therapeutics stock a Buy, while 1 rates the stock a Hold. With a return potential of 145%, the stock’s consensus target price stands at $3.50.